Merck’s $9.2B Cidara deal leads wave of high-stakes corporate acquisitions
In a series of significant corporate moves, pharmaceutical giant Merck (MRK) has agreed to acquire Cidara Therapeutics (CDTX) for approximately $9.2 billion. Meanwhile, Centerspace (CSR) is exploring potential options, including a possible sale to a US bank.
Merck will pay $221.50 per share for Cidara, marking the latest in a string of high-profile acquisitions in the medical sector. Earlier this year, Blackstone and TPG acquired Hologic for $18.3 billion, the largest medical device acquisition since 2006. Genmab acquired Merus for $8 billion, while Roche bid up to $3.5 billion for 89Bio in 2025.
In other news, Parker Hannifin (PH) is set to acquire Filtration Group for $9.25 billion. Revvity (RVTY) has completed its acquisition of ACD/Labs. Topgolf Callaway Brands (MODG) is in talks to sell its Topgolf unit to Leonard Green. Rumble (RUM) is acquiring Northern Data (OTC:NDTAF) in an all-stock deal valued at about $767 million.
Papa John's (PZZA) has dismissed takeover speculation by a PNC bank, leading to a 6.5% drop in its stock price. Day One Biopharmaceuticals (DAWN) is merging with Mersana Therapeutics (MRSN) in a deal valued up to $285 million. TreeHouse Foods (THS) is being acquired by Investindustrial in an all-cash transaction for $2.9 billion. ABN AMRO Bank (OTCPK:AAVMY, OTC:ABMRF) is acquiring NIBC Bank for around €960 million.
These strategic moves reflect the dynamic nature of the corporate landscape, with companies seeking growth and consolidation through acquisitions and mergers. The final outcomes of these transactions will shape the future of these businesses and their respective industries.
